Letrozole Sandoz (Letrozole)

Letrozole works by selectively inhibiting the aromatase enzyme (CYP19A1), which converts androgens into estrogens. By blocking this conversion, systemic estrogen concentrations fall, depriving estrogen‑dependent breast cancer cells of a key growth signal and thereby slowing tumor proliferation.

The dosage of Letrozole is individualized by the prescribing clinician based on the patient’s condition, renal and hepatic function, and treatment goals. The prescriber determines the appropriate strength and regimen; patients should follow the exact instructions provided on the prescription label.

Letrozole is contraindicated during pregnancy because it can harm the developing fetus. Its safety in breastfeeding has not been established, and it is generally advised that nursing mothers avoid the medication. Effective contraception is required for women of child‑bearing potential while on therapy.

To order Letrozole Sandoz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Letrozole belongs to the aromatase inhibitor class, similar to anastrozole and exemestane. Compared with anastrozole, Letrozole has a slightly longer half‑life and may achieve more consistent estrogen suppression, which can translate into comparable efficacy but a different side‑effect profile, especially regarding bone health.

Letrozole tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral formulation.

Letrozole is taken orally, usually once daily, with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their healthcare provider and avoid crushing or chewing the tablet unless directed otherwise.

Serious risks associated with Letrozole include severe bone loss leading to fractures, thromboembolic events such as deep‑vein thrombosis, significant liver enzyme elevations, cardiovascular complications, and rare but severe allergic reactions like anaphylaxis. Patients should report any unusual symptoms promptly.

Letrozole should not be used by women who are pregnant, planning to become pregnant, or breastfeeding. It is also contraindicated in patients with known hypersensitivity to Letrozole or any component of the formulation, and caution is advised in those with severe liver disease or uncontrolled cardiovascular conditions.